대한핵의학회지 (1967년~2009년)
Nucl Med Mol Imaging 2008;42(Suppl)1~5
뇌종양에서의 18F-FDG PET의 임상 이용
(Clinical Application of 18F-FDG PET in Brain Tumors)
Author 홍일기1, 김재승2,
Il Ki Hong1, Jae Seung Kim2
Affiliation 한양대학교 의과대학 핵의학교실1, 울산의대 서울아산병원 핵의학과2
1Department of Nuclear Medicine, College of Medicine, Hanyang University, Seoul, Korea, 2Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Abstract

Primary brain tumor accounts for 1.4% of entire cancer. For males between the ages of 15 and 34 years, central nervous system tumors account for the leading cause of cancer death. 18F-FDG PET has been reported that it can provide important diagnostic information relating to tumor grading and differentiation from non- tumorous condition. In addition, the degree of FDG metabolism carries prognostic significance. By mapping the metabolic pattern of heterogeneous tumors, 18F-FDG PET can aid in targeting for stereotactic biopsy by selecting the subregions within the tumor that are most hypermetabolic and potentially have the highest grade. According to clinical research data, FDG PET is expected to be a helpful diagnostic tool in the management of brain tumors. (Nucl Med Mol Imaging 2008;42(suppl 1):1-5) Key Words: brain neoplasm, 18F-FDG, positron emission tomography

Keyword brain neoplasm, 18F-FDG, positron emission tomography
Full text Article 42s1.pdf 42s1.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)